Related Experiment Video
Updated: Jul 6, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary
David E Lanfear1, Philip G Jones, Sharon Marsh
1Departments of Medicine, Genetics, and Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis, Mo;
JAMA
|September 29, 2005
Summary
Beta-adrenergic receptor (ADRB2) gene variations impact survival in acute coronary syndrome patients on beta-blocker therapy. Specific ADRB2 genotypes are linked to differential mortality rates, suggesting personalized treatment approaches.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Previous studies suggest a link between beta-adrenergic receptor gene polymorphisms and response to beta-blocker therapy.
- However, no direct association with mortality has been established.
Purpose of the Study:
- To investigate the impact of specific beta-adrenergic receptor (ADRB1 and ADRB2) gene polymorphisms on 3-year survival in acute coronary syndrome (ACS) patients treated with beta-blockers.
- To determine if ADRB1 Arg389Gly, Ser49Gly, and ADRB2 Gly16Arg, Gln27Glu genotypes influence mortality post-ACS.
Main Methods:
- A prospective cohort study involving 597 ACS patients discharged on beta-blocker therapy.
- Analysis of multivariable-adjusted, all-cause 3-year mortality.
- Genotyping for ADRB1 Arg389Gly (1165 CG), Ser49Gly (145 AG), and ADRB2 Gly16Arg (46 GA), Gln27Glu (79 CG) polymorphisms.
Main Results:
- A significant association was found between ADRB2 genotypes and 3-year mortality in patients receiving beta-blockers.
- Specific ADRB2 polymorphisms (79 CG and 46 GA) showed differential mortality rates, with certain genotypes linked to reduced risk.
- No significant mortality differences were observed for ADRB1 variants or in patients not on beta-blocker therapy.
Conclusions:
- ADRB2 gene polymorphisms influence survival outcomes in ACS patients treated with beta-blockers.
- These findings suggest a potential role for pharmacogenomics in tailoring beta-blocker therapy for improved patient survival.
- Further research into the benefits of beta-blocker therapy in high-risk ADRB2 genotype groups is warranted.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...